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E-mail address: manuel@graeber.net (M.B. GraebeThere is increasing confusion about the meaning of the terms inﬂammation, neuroinﬂammation,
and microglial inﬂammation. We aim in this review to achieve greater clarity regarding these terms,
which are essential for our understanding of the role of microglia in CNS inﬂammatory conditions.
The important concept of sterile inﬂammation is explained against the backdrop of classical inﬂam-
mation, and its key differences from what researchers refer to when they use the terms neuroin-
ﬂammation and microglial inﬂammation are illustrated. We propose to replace the term
‘‘neuroinﬂammation’’ with ‘‘microglial activation’’ or ‘‘CNS pseudo-inﬂammation’’, if microglial acti-
vation does not sufﬁce. In addition, we recommend abandoning the terms ‘‘microglial inﬂamma-
tion’’ and ‘‘inﬂamed microglia’’ because of the lack of a clear concept behind them.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Before we can consider the role of microglia (Fig. 1 illustrates
their phenotypic plasticity) in central nervous system (CNS) inﬂam-
mation, we have to deﬁne what inﬂammation in the CNS context
means and how the term neuroinﬂammation is used in comparison.
This is necessary because inﬂammation has become an ‘‘abused’’
term [1]. Historically (2000 years ago), the Roman Celsus is credited
as ﬁrst documenting the four cardinal signs of inﬂammation: rubor
et tumor cum calore et dolore (redness and swelling with heat and
pain); the ﬁfth cardinal sign – functio laesa, loss of function – was
added by Virchow in 1871 [1]. This descriptive and clinical deﬁni-
tion of classical inﬂammation is still in use and dominates conven-
tional thinking. However, it is only the tissue correlate of the
cardinal symptoms, i.e., cellular inﬂammatory changes, that is read-
ily applicable to CNS pathology. Moreover, in recent years new
models of inﬂammation have been developed that are based on
molecular phenomena rather than rooted in a cellular understand-
ing of inﬂammation. The problem with some of these molecular
models is that experimental results are sometimes uncritically
translated into clinical medicine and may have signiﬁcant impactcal Societies. Published by Elsevier
r).on anti-inﬂammatory treatments and the use of anti-inﬂammatory
drugs, even though the indications and expected beneﬁts remain
far from evidence-based [2]. Every year about 120 billion aspirin
tablets are consumed worldwide and contribute to an estimated
100 000 hospital admissions and 16 500 deaths in older people
from non-steroidal anti-inﬂammatory drug (NSAID)-related gastro-
intestinal complications [2]. As we aim to show in this review,
‘‘neuroinﬂammation’’ represents an evenmore difﬁcult concept than
inﬂammation and a related term often used in connection with
microglia, ‘‘microglial inﬂammation’’ adds confusion. The problem
is further aggravated by reviews that propagandize hypothetical
roles for the innate and adaptive immune system in common neu-
rodegenerative diseases (Virchow did not provide descriptions of
activated microglia as claimed by the same authors) [3].
In his classical textbook on the histopathology of the CNS [4],
Spielmeyer points out that the conceptof inﬂammationposes amost
difﬁcult problemto both the researcher and the teacher. Speciﬁcally,
the interpretation and evaluation of its competing individual
processes are asdifﬁcult as formulatinga cleardeﬁnitionof the term.
Yet, there appear to be some basic and universally recognized
principles of inﬂammation that can be summarized and applied to
most if not all organ systems. Clearly classical inﬂammation, which
involves participation of the body’s peripheral innate and adaptive
immune systems can affect the brain and spinal cord.B.V. Open access under CC BY-NC-ND license.
Fig. 1. (A) Microglia and brain macrophages in the cerebral cortex during subacute ‘decay of tissue’ (Zerfallsprozess). Red colour represents lipid staining (Haematoxylin-
scarlet red). Cells become more round with increasing lipid uptake. (B, C) A brain macrophage (arrow) that has taken up a myelin fragment (blue). Chronic multiple sclerosis.
Luxol fast blue-PAS. Figure A taken from [4]. Scale bar: 10 lm.
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discussion of processes that nobody would doubt are clearly
inﬂammatory. Poliomyelitis and other infectious diseases represent
good examples. From a histological point of view these diseases are
characterized by the presence of inﬁltrating mobile cells of the
innate immune system including granulocytes and macrophages.
These mobile cells may so dominate the histological appearance
that inﬂammation is sometimes equated with this reactive inﬁltra-
tion. The latter is incorrect but the presence of mobile cells, most of
which have originated outside the affected tissue, is the most
widely recognised sign of an inﬂammatory process. Thus, the cellu-
lar elements within inﬂamed tissue consist of two groups: resident
and mobile cells.
2. Classical inﬂammation
Examples of classical inﬂammation in the central nervous sys-
tem include the response to bacterial, parasitic or viral infections.
As already indicated, a deﬁning feature of classical inﬂammation is
the accumulation of mobile innate and/or adaptive immune cells
in the tissue that are recruited via the bloodstream; although
some may also proliferate locally [5]. The latter is certainly true
for the microglia of the CNS which, unlike peripheral tissue mac-
rophages, have retained a strong proliferative potential. In addi-
tion to the invasion of mobile cells, the classical patho-
anatomical deﬁnition of inﬂammation includes a vascular, prolif-
erative and parenchymal tissue-altering component. Traditionally,
the term inﬂammation is applied not only to the reaction associ-
ated with, for example, an acute or chronic infection or followingtoxic damage but also to the reaction accompanying or following
tissue repair and regeneration [4]. Recruitment of peripheral mo-
bile cells to the site of inﬂammation varies. In acute inﬂammation,
if neutrophil recruitment into a tissue is sufﬁciently pronounced
they become visible as pus [6]. The inﬁltrating mobile cells may
also cause tissue destruction. It is worth emphasizing at this point
that neutrophils (granulocytes) are far more tissue destructive
than macrophages [6] especially when the latter are in a M2-
polarised state (CD163 positive) which has been linked to tissue
repair. Interestingly, the microglia in the Parkinsonian substantia
nigra show this phenotype [7]. Characteristically, granulocytes
(Fig. 2 demonstrates their characteristic segmented nuclei) are
not seen in conditions that are commonly referred to as ‘‘neuroin-
ﬂammatory’’ (for a deﬁnition of this term see the section on neur-
oinﬂammation). The innate immune system in the CNS, in
addition to microglia, includes perivascular macrophages (non-
committally termed ‘‘perivascular cells’’). These cells are anatom-
ically and functionally distinct from microglia and serve as the
ﬁrst line of CNS defense. They can be thought of as forming an
‘‘immunological blood–brain barrier’’ [8]. Classical inﬂammation
involves both cell populations.
The fundamental processes that give rise to the cardinal symp-
toms and signs of classical inﬂammation (Celsus) are centered on
and result from changes in the local vasculature [4,6]. In other
words, it is the vasculature where the actual inﬂammation begins
with the consequence that every inﬂammatory process is predom-
inantly if not exclusively interstitial. In the CNS, an unavoidable
consequence of classical inﬂammation is compromise of the
blood-brain barrier.
Fig. 2. Purulent myelitis. Destruction of central portions of the cord (ep = remnant of ependyma). Nissl staining. Note the polymorphism of the leukocyte nuclei. Taken from
[4].
3800 M.B. Graeber et al. / FEBS Letters 585 (2011) 3798–3805Although some authors seem to suggest that inﬂammation can
be an exclusively cellular event and have coined the term ‘‘in-
ﬂamed microglia’’, we believe that the term inﬂammation should
only be used when referring to the classical multicellular process
characterized by changes in the vasculature and inﬁltration of mo-
bile cells. An expanded uncritical use of the term inﬂammation
causes confusion.
One role of histology lies in clarifying whether inﬂammatory
tissue changes represent the primary pathological process or
whether they are merely associated secondary phenomena. The
latter has been named symptomatic or secondary inﬂammation [4].
In our opinion, it is not appropriate to equate all tissue responses
with inﬂammation.
3. Sterile inﬂammation
Inﬂammation as a result of trauma, ischaemia–reperfusion
injury or chemically induced injury occurs in the absence of micro-
organisms and has been termed sterile inﬂammation [9]. Examples
of inducers of sterile inﬂammation include cholesterol crystals
[10], hyaluronan [10] and uric acid [6]. The question of how a cell
that does not induce inﬂammation when alive becomes proinﬂam-
matory after death is of great interest [6]. One of the presently
favored models is that after dying, proinﬂammatory molecules,
normally intracellular and hidden by the plasma membrane, are
released from the cell [6].
The inﬂammasome, a large multimeric intracellular complex
that regulates activation of caspase-1 becomes directly and indi-rectly activated not only during infection or injury but also during
sterile inﬂammation [6,10]. Similar to microbially induced inﬂam-
mation, sterile inﬂammation is characterized by a recruitment of
neutrophils and macrophages and the production of proinﬂamma-
tory cytokines and chemokines, notably tumor necrosis factor
(TNF) and interleukin-1 (IL-1) [9]. Under conditions of sterile cell
death, the inﬂammatory response, and particularly the inﬁltration
of tissues with neutrophils, can increase the amount of tissue in-
jury [6].
4. Neuroinﬂammation
A PubMed search for ‘‘neuroinﬂammation’’ yields more than
2400 hits and indicates that the term was ﬁrst used in a publica-
tion about 15 years ago. A few years into the new millennium,
the Journal of Neuroinﬂammation was founded which deﬁnes its
scope as a journal that focuses on ‘‘innate immunological re-
sponses of the nervous system, involving microglia, astrocytes,
cytokines, chemokines, and related molecular processes’’. About
one third of the PubMed articles containing the term neuroinﬂam-
mation also contain ‘‘microglia’’; twice as many as contain ‘‘astro-
cytes’’ and far more than include ‘‘lymphocytes’’. In contrast, the
term neuroimmunology is broader and has a stronger emphasis
on cells of the peripheral immune system such as lymphocytes.
Accordingly, the Journal of Neuroimmunology deﬁnes its scope as
a ‘‘forum for the publication of works applying immunologic meth-
odology to the furtherance of the neurological sciences’’. Thus, one
would assume that the ﬁeld of neuroinﬂammation deals less with
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system’s own innate immune cells, the microglia in particular, and
their involvement in inﬂammatory reactions. However, if this is the
case then the vast majority of so-called ‘‘neuroinﬂammatory’’ con-
ditions do not fulﬁll one of the main criteria of inﬂammation,
namely the presence of mobile cells (granulocytes and/or macro-
phages and/or lymphocytes). In addition to the mentioned lack of
peripheral immune cells, neuroinﬂammatory conditions are also
not usually accompanied by a breach of the blood-brain barrier.
A third important argument against ‘‘neuroinﬂammation’’ being a
variant of inﬂammation comes from the rare human transmissible
spongiform encephalopathy, Creutzfeldt-Jakob disease (CJD). The
diagnosis of CJD requires absence of classical inﬂammatory
changes. However, microglia, the CNS’ innate immune cells, never-
theless up-regulate MHC class II molecules several hundredfold in
this condition [11]. Thus, we are left without a sound basis for
using the term neuroinﬂammation and propose to replace it with
the term ‘‘microglial activation’’, or, if this does not sufﬁce ‘‘CNS
pseudo-inﬂammation’’ where peripheral immune cells are absent
but astrocytes produce ‘‘proinﬂammatory’’ factors.
Microglial activation represents an increasingly important con-
cept which originated in the late 1980s. The term ‘‘activated
microglial cells’’ was formally introduced when it became apparent
that intrinsic (resident) microglia are capable of up-regulating cer-
tain molecules, including several that are not normally expressed
in the CNS [12–14]. Such chameleon-like behaviour illustrates
the now well-recognized phenotypic and functional plasticity of
microglia [15]. However there remain problems distinguishing
microglia, especially after activation, from bone marrow-derived
macrophages. Even contemporary microglia markers are cell
type-speciﬁc only in the sense that they do not label other glia or
neurons. They do not readily distinguish resident microglia from
macrophages. Consequently, some have suggested that there is
no microglia-speciﬁc marker. In spite of this, as with macrophages
outside the CNS, different functional activation states have been
identiﬁed in microglia, similar to the well characterized classicalFig. 3. Perivascular ﬁbrosis of a blood vessel in a case of chronic multiple sclerosis. Th
macrophages can be seen.(M1) and alternative (M2) activation states in macrophages out-
side the CNS [16]. Taken together, microglial activation is plastic,
ﬁnely graded [12] and dynamic. Activated microglia may adopt dif-
ferent phenotypes in response to various stimuli and can become
additionally altered following secondary challenges, for example
systemic inﬂammation. There is even evidence that this activation
is brain region-speciﬁc [17].
5. Multiple sclerosis is not a neurodegenerative disease
Multiple sclerosis (MS) is a characteristic syndrome that, de-
spite protean symptoms reﬂecting the varying sites of the CNS that
can be affected by inﬂammation and demyelination, is rarely mis-
diagnosed by an experienced neurologist [18]. This is mirrored by
prototypical pathological features where perivascular mononu-
clear inﬁltrates and demyelinating lesions of various stages pre-
dominate. Perivascular inﬂammation is so pronounced that
residual ﬁbrosis of blood vessels is often found (Fig. 3 illustrates
the extent of long-standing perivascular pathology). Many believe
that inﬂammation in MS initiates tissue injury so that degenerative
changes which also occur, including axon loss, are considered sec-
ondary. It is important to mention in this context that others have
suggested that in some patients, albeit with clinically indistin-
guishable symptoms, the initial change is degenerative rather than
inﬂammatory [18]. In relation to MS, the term neurodegeneration
is commonly used to describe neuroaxonal damage [19]. While this
may or may not be related to focal demyelinating lesions, most
authors currently consider inﬂammation to be central to its path-
ogenesis [19]. This can be contrasted with classical neurodegener-
ative diseases such as Alzheimer’s disease and Parkinson’s disease,
where most authors favour a primary CNS-autonomous neurode-
generative process with no accompanying classical or sterile
inﬂammation but frequent pseudo-inﬂammatory signs, i.e.,
microglial MHC class II expression in the absence of co-stimulators
that would be required for antigen presentation leading to ae arrow points to the blood vessel’s lumen. Haemosiderin-containing perivascular
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brain pathology in general paralysis of the insane, inﬂammation,
although present does not appear to be the cause of the degenera-
tive changes [4].
It is worth remembering that in classical inﬂammation differ-
ent noxae cause different cellular inﬁltrates and subsequent tis-
sue responses. This is why the histopathology of a multiple
sclerosis plaque is characteristic and cannot be mistaken for say
an abscess. It is also important to point out that the residual state
or end stage of an inﬂammatory process needs to be distin-
guished from ongoing inﬂammation [4] so a burnt-out and highly
gliotic (sclerotic) MS plaques can be completely devoid of inﬂam-
matory cells. Nevertheless, MS is rightly considered the arche-
typal inﬂammatory disease of the CNS, which is characterized
by an immune assault on the brain and spinal cord with damage
to the myelin sheaths, axons and grey matter [20]. There also is a
contribution of systemic inﬂammation to CNS diseases including
MS: it has been shown that systemic infections, typically upper
respiratory tract infections, are associated with a signiﬁcant num-
ber of MS relapses [20]. It is further apparent that if systemic
infections exacerbate disease processes in the CNS, they may do
so by signalling across an intact blood-brain barrier, and microg-
lia could have a role in this peripheral immune system to brain
signalling [20].6. Alzheimer and Parkinson’s diseases: Inﬂammation?
In the 1980s an ‘‘imaging revolution’’ began to take place in his-
tology with the introduction of monoclonal antibodies. Antibodies
(and lectins) allowed for the ﬁrst time the visualization of biolog-
ical molecules obviating the need to rely on ill-deﬁned tinctorial
properties of human tissue and the capriciousness of histochemical
stains. The discovery of MHC molecules as markers for activated
microglia in common neurodegenerative conditions such as Par-
kinson’s and Alzheimer’s diseases (PD and AD) by the McGeer
group [21–23] represented a landmark of microglia research which
coincided with convergent ﬁndings in an experimental, facial nerve
axotomy model [24,25]. The description of de novo expression of
MHC molecules in the CNS in the conspicuous absence of periphe-
ral immune cells arguably marked the beginning of a paradigm
shift. Before this time, researchers mainly looked at immunological
phenomena in the CNS ‘‘through the eyes of the T-cell’’. Subse-
quently, the work of McGeer and colleagues has been used as evi-
dence that inﬂammation has a key role in AD and PD, and this
development has gained additional momentum in recent years.
Claims are now being made that microglial activation is one of
the causative factors for neuroinﬂammation, which results in brain
damage during neurodegenerative disease [26]. As a consequence,
since microglial activation is thought to play an important role in
the pathophysiology of neurodegenerative diseases, suppression
of microglial activation is hypothesized to prevent the progression
of neurodegeneration [27]. While it is still recognised by some
authors that inﬂammation may not typically represent an initiat-
ing factor in neurodegenerative diseases, the idea of inﬂammation
being present in essentially all common neurodegenerative condi-
tions is widely publicized: ‘‘direct evidence for an innate inﬂam-
matory response in AD was described nearly 20 years ago, and
subsequent studies have documented inﬂammatory components
in PD, amyotrophic lateral sclerosis (ALS), MS, and a growing num-
ber of other nervous system pathologies’’ [3]. This statement is
remarkable because it seems to imply a degree of relatedness be-
tween MS, a long-established prototypical inﬂammatory disease,
and diseases such as AD, PD and ALS. Not surprisingly, treatments
such as rifampicin for ‘‘microglial inﬂammation’’ in neurodegener-
ative diseases have already been proposed [27].Parkinson’s disease
The concept of inﬂammation acting as a major factor in the
pathogenesis of PD can be summarized as follows [28]: ‘‘Neuroin-
ﬂammation, which is characterized by activated microglia and
inﬁltrating T cells at sites of neuronal injury, is a prominent
contributor to the pathogenesis of progressive PD. Microglia play
a critical role in forming a self-propelling cycle leading to sustained
chronic neuroinﬂammation and driving the progressive
neurodegeneration in PD. This activation depends heavily on the
respiratory burst within the microglia, which in turn regulates a
number of downstream pro-inﬂammatory activities. On the other
hand, the adaptive immune responses, most notably T cells, are
now emerging as important components of the inﬂammatory re-
sponse that contributes to the pathogenesis of PD.’’ Other authors
suggest that activated microglia are widely considered to partici-
pate in the progression of PD [29] and advocate a role for the im-
mune system in PD [30]. In PD animal models caused by
intoxicating mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP), the cellular reaction includes MHC class I and II posi-
tive microglia, reactive astrocytes and T cells that inﬁltrate the
substantia nigra and striatum and gather in the meninges [31].
However, at least in somemodel systems, T cell inﬁltration appears
to be species speciﬁc. So in a facial nerve injury model, peripheral
axotomy results in T cell inﬁltration into the facial nucleus of the
mouse but not the rat (whose neurobiology seems closer to hu-
mans) [32]. Some authors even believe that speciﬁc T-cell subsets
inﬂuence PD progression [29]. Yet, this must sound extremely pe-
culiar to anyone who has seen a large number of human PD sub-
stantiae nigrae with their striking absence of lymphocytes, or a
substantia nigra included in a plaque of multiple sclerosis. The lat-
ter is not rare and provides a very informative example of what
true inﬂammatory damage to the human substantia nigra looks
like. If one also takes into account that microglia in the PD nigra ex-
hibit an anti-inﬂammatory phenotype [7], one remains uncon-
vinced of the inﬂammatory theory of PD. This scepticism seems
additionally justiﬁed in light of a recent report demonstrating that
up-regulation of microglial C1q expression has no effect on nigro-
striatal dopaminergic injury in the MPTP mouse model of Parkin-
son’s disease [33]. Instead, complement may well be involved in
synaptic changes [34]. While we do not question that genes in-
volved in inﬂammatory reactions in the periphery are speciﬁcally
up-regulated in the human PD substantia nigra, as our own work
has demonstrated [35], it seems increasingly likely that the prod-
ucts of these genes have a dual and thus different function in the
CNS. This view is in keeping with the results of a very large obser-
vational study involving 4026 cases of idiopathic PD and 15 969
matched controls [36] where it was found that the long-term use
of NSAIDs, aspirin, or acetaminophen was not associated with a
substantially altered risk of developing PD [36].Alzheimer’s disease
The enormous interest in inﬂammation in AD is comparable to
that in PD and has a similar historical background [21,22,37]. The
driving motivation is also similar, i.e., to develop anti-inﬂamma-
tory therapies that, while they may not cure AD, will hopefully
help slow the progression or delay the onset of this disorder [38].
Yet, NSAIDs were not found to ameliorate Alzheimer neuropathol-
ogy [37]. Therefore, it is possible, if not likely in our view that acti-
vated microglia, identiﬁed in the brains of Alzheimer disease
patients both histopathologically and in neuroimaging studies
[39], and now commonly referred to as ‘‘neuroinﬂammatory’’,
may have a completely different function to activated macro-
phages in the periphery. For instance, we now know that microglia
M.B. Graeber et al. / FEBS Letters 585 (2011) 3798–3805 3803themselves are affected by the disease process in AD [40]. There-
fore, MHC class II upregulation rather than indicating preparedness
of the microglia to engage in a secondary (‘‘recall’’) immune reac-
tion in AD, which should be accompanied by components of the
classical inﬂammatory response (which are typically absent from
AD brains), these activated microglia could be interpreted as
microglia trying to protect already damaged brain tissue [7]. This
could explain why anti-inﬂammatory drugs in AD and PD do not
have the desired beneﬁcial effects.
Microglial activation may also be a response to neuronal loss as
well as to neuronal dysfunction and their extremely low activation
threshold results in their almost universal involvement in even
subtle brain pathologies [41]. So in neurodegenerative diseases,
widespread microglial activation may reﬂect widespread neuronal
dysfunction in addition to the more apparent alterations of syn-
apses. Direct neuronal attack by microglia (neuronophagia) is
tightly controlled, rare and, in all likelihood, a secondary phenom-
enon [7]. The observation, by human neuropathologists, that
microglia do not indiscriminately attack nerve cells in vivo sug-
gests that effective neurotoxicity by activated microglia in the ab-
sence of granulocytes or T cells is unlikely or at least uncommon.
So while microglial activation may be associated with neuronal
loss in neurodegenerative diseases, it is more likely a response to
neuronal loss than the cause.7. Neuroimmunology of psychiatric disorders
Results obtained from imaging activated microglia in vivo [39]
have fostered an interest in the role of microglia in psychiatric dis-
eases. Microglial activation, which many authors effectively equate
with neuroinﬂammation, is now considered to be central to the
pathogenesis of several psychiatric disorders. Moreover, neuroin-
ﬂammation has been suggested to involve glial cell-propagated
inﬂammation [42] – in the striking absence of signs of inﬂamma-
tion at the microscopic level. Possibly, researchers in psychiatry
(often even more remote from human tissue than basic neurosci-
entists) do not distinguish between inﬂammation and neuroin-
ﬂammation (microglial activation).
Based on the presence of activated microglia, and the recogni-
tion that inﬂammation may represent a common mechanism of
disease, some authors have suggested that inﬂammation is impor-
tant in the pathophysiology of a number of neuropsychiatric disor-
ders including major depression [43]. One often used argument is
that patients with major depression show increased peripheral
blood inﬂammatory biomarkers, including inﬂammatory cytokines
[44]. Indeed, in response to a peripheral infection, pro-inﬂamma-
tory cytokines are produced by innate immune cells that have an
effect on the brain causing sickness behaviour, which may explain
the increased prevalence of clinical depression in physically ill peo-
ple [45]. However, neuropathological criteria of inﬂammation are
again not fulﬁlled. One author even hypothesizes that ‘‘progress
from depression to dementia could result from the activation of
macrophages in the blood, and microglia in the brain, that release
pro-inﬂammatory cytokines’’ [46] but there is no histological evi-
dence to back this up. Consequently, it appears as though psychia-
try is close to adopting a ‘‘neuroinﬂammation theory of mental
diseases’’. However, we concur with Bhat and Steinmann [47] that
one must look at the boundaries of neurobiology and immunology
with a healthy dose of skepticism. It is obvious that there is a great
need for more human brain tissue-based studies of psychiatric dis-
orders so that thorough and detailed neuroimaging-tissue correla-
tions can be carried out using brains from donors with a
pathologically validated cause of death and information on periph-
eral co-morbidities. In the absence of convincing evidence and thus
a clear rationale, suggestions to target proinﬂammatory cytokinesand inﬂammation signaling pathways as a strategy to treat psychi-
atric patients have to be considered premature.8. Role of microglia in normal brain
Althoughmicroglia can express ‘‘immunemolecules’’, this is not
synonymous with inﬂammation, since these molecules can have
CNS-speciﬁc roles independent of their roles in the immune or
inﬂammatory response [41]. Similarly, molecules known to
neurobiology, including gamma amino butyric acid and the lens
protein alpha B crystallin can have intriguing and distinct functions
in the immune system [47]. Recently, MHC class I antigens have
been implicated in synaptic plasticity and memory function [48].
Tissue damage and classic inﬂammation could therefore lead to
changes in synaptic plasticity and memory function via dysregula-
tion of MHC class I expression [48]. Other important molecules in
this context are complement and the CR3 complement receptor
[34,41]. Furthermore, the microglial inﬂammatory signaling mole-
cule DAP-12 has been found to play a role in synaptic plasticity and
in modulating glutamatergic neurotransmission [49], and Four-
geaud and Boulang have pointed out a role for immune molecules
in the establishment and plasticity of glutamatergic synapses [50].
These mechanisms could underlie the observation that a periphe-
ral inﬂammatory challenge (lipopolysaccharide injection) results
in the parallel activation of microglia and alterations in dendritic
spine dynamics [51].
Recently it has been shown that microglial interactions with
synapses are physiological and can be modulated by visual experi-
ence [52]. During development, microglia actively engulf synaptic
material and play a major role in synaptic pruning [53]. It is likely
that these normal microglial functions will continue, although per-
haps in a somewhat modiﬁed way, when various stresses caused
by disease impact on the CNS. Importantly, from a quantitative
point of view, if conﬁrmed, these normal synapse and spine mod-
ulating functions of microglia, are likely to be much more impor-
tant than their functions as part of an inﬂammatory response
which are utilized only under exceptional circumstances.
It is not usually discussed that microglia differ from all other
members of the myeloid lineage in that they live within an electric
organ. They also accumulate large amounts of the ‘‘model super-
paramagnet’’ ferritin [54] which can be used as a marker for these
cells [55] and although iron metabolism is strictly controlled in the
normal CNS where capillaries possess transferrin receptors [56],
microglia accumulate iron in a number of degenerative diseases.
Although currently speculative, microglia may be in a position to
sense pathological alterations of electromagnetic ﬁelds, which
are generated by axons as well as dendrites [57]. Interestingly, a
shared feature of both dendrites and microglia in the cerebral cor-
tex is the presence of angular branching processes; almost as
though one was modelled on the other. In contrast, in white mat-
ter, microglia are elongated. Unlike astrocytes, microglia are not
connected via gap junctions and do not normally respond as a pop-
ulation. Consequently, regional activation of microglia may indi-
cate the presence of a pathological factor that is able to stimulate
a large number of individual cells.
Any inﬂammatory reaction in the brainmust be highly regulated
to minimize neuronal damage because neurons exhibit a marked
sensitivity to inﬂammatory stimuli such as cytokines [49]. The fact
that immune proteins also have normal functions in brain develop-
ment and plasticity adds novel, non-immune dimensions to their
potential role in pathological processes [58]. Understanding how
immune proteins in the CNS are regulated by inﬂammatory signals
should provide important clues as to how peripheral immune sig-
naling may affect brain structure and function, and how changes
in the expression or function of immune proteins could affect brain
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ment and modiﬁcation of brain circuitry [58].
9. Microglial inﬂammation
It is not compatible with neuropathological diagnostic experi-
ence and thinking [4] to include isolated MHC class II immunoreac-
tive microglia under the rubric of inﬂammation in the conspicuous
absence of cells of the peripheral immune system. The tissue
responses accompanying degeneration in diseases such as AD or
PD are not ‘‘inﬂammatory’’ in the strict sense but are more appro-
priately termed microglial activation or pseudo-inﬂammation as
detailed earlier. It is the degenerative process, that is at the core
of the pathological cascade of events and this has nothing to dowith
inﬂammation. Thus, the term inﬂammation should be reserved for
processes where inﬂammation represents a primary or independent
process. Based on this deﬁnition, one could argue that the mobile
cells in the vicinity of a brain area affected by ischemia (stroke),
although they may well serve a repair function, do not represent
the essence of the ongoing pathology and hence should not be in-
cluded as ‘‘inﬂammation’’ since they are secondary changes. Indeed,
Spielmeyer suggested the term symptomatic inﬂammation for this.
In this context, ‘‘microglial inﬂammation’’, is a misnomer since
it is neither inﬂammation of the microglia nor does the phenome-
non of microglial activation correlate with inﬂammation of the
brain and spinal cord tissue. The more precise and far more appro-
priate term for this is microglia activation which encompasses both
the non-immune and immune functions of the microglia. The last
thing one would want to see is clinicians jumping the gun and
starting to treat ‘‘microglial inﬂammation’’ with anti-inﬂammatory
agents in spite of a fundamental lack of evidence that it will do the
patient good. Words become obsolete when they lose their useful-
ness. In our opinion, the terms neuroinﬂammation and microglial
inﬂammation are being applied so widely and so uncritically that
they have effectively lost their meaning. Recent additions to the
‘‘inﬂammation spectrum’’ of brain disease include epilepsy [59],
neurogenesis [60], obesity in mood disorders [61], and alcoholism
[62]. While inﬂammation in the CNS does employ some of the
same molecules and processes that occur in both peripheral local
and systemic inﬂammation, the presence of these molecules per
se should not be considered as inﬂammation of brain tissue [62].
Thus, although what is termed ’’neuroinﬂammation’’ is often con-
sidered to be the equivalent of inﬂammation in the periphery,
these two pathological responses are clearly different [62].10. Role of microglia in CNS inﬂammation
In addition to microglia, the normal CNS parenchyma harbors
two other glial cell types that have to be considered in the context
of brain and spinal cord inﬂammation. Astrocytes are not com-
monly associated with immunological reactions and it is well ac-
cepted that their role in CNS immunity is largely regulatory
while their contribution and capacity to present antigen and acti-
vate T cells are still controversial [63]. Oligodendrocytes also do
not seem to exert signiﬁcant immunological or inﬂammatory func-
tions. Microglia in contrast can serve as activators of naive T cells
but probably more importantly, have a role in the reactivation of
T cells inﬁltrating the CNS, i.e., during secondary (recall) reactions
and in autoimmune conditions such as MS [63]. Microglia express
co-stimulatory and MHC molecules on demand and are capable of
presenting antigen to T cells more effectively than astrocytes but
less efﬁciently than dendritic cells [63]. Thus, amongst the CNS res-
ident parenchymal cells, microglia are of greatest interest in the
context of neuroimmunology.Although we introduced the concept of the microglial immune
network two decades ago [64] we remain unconvinced that im-
mune and inﬂammation-related activity is the main function of
microglia. It seems more likely to us that their main role is in syn-
aptic plasticity and in the maintenance of synaptic integrity in par-
ticular. While there is no doubt that microglia are a CNS tissue
alarm system (Kreutzberg’s sensor of pathology), the majority of
their daily challenges are likely to be subclinical. It is quite conceiv-
able therefore that many of the phenomena in the CNS currently
categorized as ‘‘inﬂammatory’’ represent nothing more than
microglia in an increased state of alertness and activity.
An important consequence of considering CNS inﬂammation
and distinguishing it from microglial activation is to reinforce the
precautionary clinical principle: primum nil nocere. This means
that at the present time a clinical diagnosis of ‘‘neuroinﬂamma-
tion’’ does not provide a sufﬁcient rationale for treatment with
anti-inﬂammatory agents. We do agree however that dissecting
the immune component of neurologic disorders represents a grand
challenge for the 21st century [65].References
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